Target species
Cattle & pigs.
Indications for use for each target species
In cattle: Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E. coli mastitis.
In pigs: Indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by susceptible strains of organisms.
Contra-indications
Do not use in cases of resistance to other fluoroquinolones (cross-resistance).
Do not use in cases of hypersensitivity to the active substance, to any other quinolone or to any of the excipients.
Special warnings
None
Special precautions for use
Special precautions for safe use in the target species:
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to (fluoro)quinolones, such as marbofloxacin, should avoid contact with this veterinary medicinal product.
In case of contact with skin or eyes, rinse with plenty of water. Accidental self-injection can induce a slight irritation.
In case of accidental self-injection, seek medical advice and show the package leaflet or label to the physician.
Wash hands after use.
Special precautions for the protection of the environment:
Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.
Adverse events
Cattle and swine:
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Injection site inflammation1 |
1 Transitory
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder
or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation:
May be used in pregnant and lactating cows and sows.
Interaction with other medicinal products and other forms of interaction
None
Administration routes and doseage
The recommended dosage is 2mg/kg/day (1ml/50kg) in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs.
Treatment durations are 3 days in pigs and 3 to 5 days in cattle.
In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Overdosage may cause acute signs in the form of neurological disorders which would have to be treated symptomatically.
No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
Withdrawal period(s)
Cattle
Meat and offal: 6 days
Milk: 36 hours
Pigs
Meat and offal: 4 days